SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

Alternative Plants is a biotech start-up that establishes plant stem cell cultures for effective, consistent and sustainable production of cosmetic active ingredients. Our focus is on medicinal plants that are difficult to grow, are rare or even endangered, so our plant stem cell culture technology is the only way to access the valuable substances that they produce. Our current focus is on cosmetic active ingredients market. Our clients are cosmetic manufacturers that use our plant stem cell derived active substances as key active ingredients in their products. In the same time we clearly see that with our technology we can later expand to other markets as functional foods, medical devices and pharma as well.

Artyc specializes in cold shipping solutions for biotech, pharmaceutical, and medical goods. The company focuses on creating sustainable logistics by providing refrigerant-free, reusable, active cooling containers. These innovative containers are designed to decarbonize the cold chain, thereby promoting a more environmentally friendly logistics industry. By utilizing Artyc's containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring, ensuring that sensitive products are transported safely and efficiently.

Artyc specializes in cold shipping solutions for biotech, pharmaceutical, and medical goods. The company focuses on creating sustainable logistics by providing refrigerant-free, reusable, active cooling containers. These innovative containers are designed to decarbonize the cold chain, thereby promoting a more environmentally friendly logistics industry. By utilizing Artyc's containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring, ensuring that sensitive products are transported safely and efficiently.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Solving gout using engineered probiotics

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Pyrone Systems develops biopesticides that combine biology with chemistry. The company was founded in 2021.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Pyrone Systems develops biopesticides that combine biology with chemistry. The company was founded in 2021.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

CyGenica specializes in developing innovative delivery solutions for drugs, gene editing components, and antibiotics using a non-viral, non-toxic platform. The company focuses on creating molecular devices that facilitate the programmable delivery of anticancer drugs and other therapeutic agents directly into cells. These devices are designed to cross cellular membrane barriers, allowing for the effective transport of functional molecules into the cytoplasm and various cellular organelles. By enabling pharmaceutical and biotechnology companies to develop new types of anticancer drugs with extended brand lifecycles, CyGenica aims to enhance the efficacy and safety of medical treatments.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

Medical Devices Corner specializes in providing commercial medical products.

Wayfinder Biosciences develops biosensors for ultra-high-throughput screening for high-value molecules. The company's PerfectPath biosensors make invisible molecules visible. These biosensors generate fluorescence based on the concentration of the desired small-molecule — allowing quantification of product titer at high-throughput using fast fluorescence measurements. Wayfinder Biosciences was established in 2021 and is headquartered in San Francisco, CA.

Wayfinder Biosciences develops biosensors for ultra-high-throughput screening for high-value molecules. The company's PerfectPath biosensors make invisible molecules visible. These biosensors generate fluorescence based on the concentration of the desired small-molecule — allowing quantification of product titer at high-throughput using fast fluorescence measurements. Wayfinder Biosciences was established in 2021 and is headquartered in San Francisco, CA.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

In India, 1 in 4 people suffer from chronic ailments. Meanwhile, 80% of patients cannot comply to the treatment plan provided by the doctor leading to even more complications. This poses a huge burden on the healthcare system. Phable solves this by making care autonomous and predictive. Our AI-enabled health assistant significantly improves health outcomes by enabling disease-specific guidance and continuous monitoring. Phable is marching onward to impact a billion lives over the next 5 years.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Chinova Bioworks Inc. specializes in developing natural antimicrobials for the beverage industry, focusing on enhancing the shelf life of fresh juices. Founded in 2016 and based in Fredericton, Canada, the company utilizes a chitosan polymer derived from fungal-sourced technology, specifically natural fibers from mushrooms. This broad-spectrum preservative effectively protects products from spoilage while remaining a healthy, natural ingredient suitable for use in foods, beverages, cosmetics, and personal care items. By providing manufacturers with a solution to improve product quality and freshness, Chinova Bioworks aims to increase consumer satisfaction and reduce food waste.

Transforming the performance of protein powders through our patent-pending Ingredient Optimization process to increase sustainability and improve health outcomes.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

SyntheX, Inc. is a biotechnology company that focuses on drug discovery through a unique screening platform designed to identify and design therapeutics for oncology and other biotechnological applications. Founded in 2016 and based in San Francisco, SyntheX utilizes a synthetic biology-driven approach to efficiently synthesize and identify peptides and macrocycles that disrupt specific intracellular protein-protein interactions. The company’s development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating certain cancers that evade chemotherapy through homologous recombination. By leveraging genetically engineered circuits and proprietary DNA-encoded libraries, SyntheX targets drug discovery based on synthetic lethality and oncogene addiction, with an emphasis on addressing DNA damage repair and novel cell death mechanisms.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

Feel Therapeutics, based in San Francisco, is focused on transforming mental health management through its innovative digital precision medicine platform. The company has developed an emotion-sensing wristband and accompanying app that provide continuous monitoring and real-time personalized interventions for individuals experiencing anxiety and depression. This comprehensive solution includes the Feel Emotion Sensor, Feel App, Feel Therapist, and an Educational Program, all designed to leverage evidence-based behavioral techniques such as Cognitive Behavioral Therapy, Mindfulness, and Positive Psychology. By integrating proprietary medical-grade wearables and advanced algorithms, Feel Therapeutics aims to deliver objective data and passive monitoring, ultimately enhancing users' mental well-being and fostering lasting positive emotional habits.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Metabolomic Diagnostics Ltd. is a medical diagnostics company based in Little Island, Ireland, specializing in the early detection of pregnancy-related complications through innovative biomarker-based diagnostic solutions. Founded in 2011, the company has developed a mass spectrometry-based platform capable of analyzing multiple biomarkers simultaneously. This technology facilitates the predictive diagnosis of pre-eclampsia, a serious condition characterized by high blood pressure and proteinuria during pregnancy. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve personalized care for pregnant women. The company's vision includes enhancing clinical decision-making and prenatal care by providing accurate risk assessments for complications such as gestational diabetes and preterm birth. Through collaboration with prenatal care providers, Metabolomic Diagnostics seeks to empower clinicians and pregnant women alike, ultimately aiming to improve pregnancy outcomes on a global scale.

Developing hardware for manufacturing next-generation medicines.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Developing hardware for manufacturing next-generation medicines.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

Valanx Biotech GmbH, founded in 2017 and based in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company focuses on creating SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with therapeutic agents to produce antibody-drug conjugates for cancer treatment. This technology also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Valanx Biotech offers bioanalytics and mass spectrometry services to meet specific client needs, enhancing the efficiency and effectiveness of protein-drug conjugate development.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Farma Genetix is a Boston-based company that specializes in the manufacture of genetically tailored natural supplements and personalized diet plans aimed at addressing chronic health conditions. The company collaborates with researchers from Harvard Medical School's Genomics department to develop nutritional supplements designed to support cardiovascular health, including the maintenance of healthy blood pressure and cholesterol levels. Through its customized diet plans, Farma Genetix promotes a holistic approach to health that reinforces overall well-being and a healthy lifestyle.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Sothic Bioscience Ltd. operates as a biotech company in Ireland. The company develops LimuleX, a bio-production platform to make bio-identical replacement for naturally sourced limulus amebocyte lysate, as well as to remove the threatened horseshoe crab species from the pharmaceutical quality control supply chain. Sothic Bioscience Ltd. was founded in 2015 and is based in Cork, Ireland.